Prostamax: Dosing Protocols
Dosing guidelines, reconstitution, and administration information
📌TL;DR
- •2 dosing protocols documented
- •Reconstitution instructions included
- •Storage: Lyophilised powder: refrigerate (2-8 C) for long-term storage. Reconstituted solution: refrigerate and use within 14-28 days per general short-peptide guidance. No Prostamax-specific stability data are available in PubMed-indexed literature.
| Purpose | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| Reported Khavinson bioregulation-clinic course (BPH context) | Low microgram per kilogram range (reported, not validated) | Daily during course | 10-20 days, then extended off-period | Reported from Russian clinic practice; not PubMed-indexed; not validated by randomised trial. Route was historically oral (sublingual) in early Khavinson framework. |
| Community-reported subcutaneous protocol | 1-2 mg per injection (community-reported) | Daily or every other day | 10-20 days per course | Community-sourced from forums and vendor packaging; no PubMed-indexed pharmacokinetic basis. Subcutaneous bioavailability of KEDP in humans has not been characterised in indexed literature. |
Unlock full dosage protocols
Free access to complete dosing tables and protocol details.
150+ peptide profiles · 30+ comparisons · 18 research tools
Dosing protocol timeline for Prostamax
Infographic pending generation
Administration guide for Prostamax
Infographic pending generation
💉Reconstitution Instructions
Prostamax is typically sold as a lyophilised powder. Reconstitution with bacteriostatic 0.9% sodium chloride is the standard handling for short peptides; however, no manufacturer with FDA-recognised cGMP status produces Prostamax, so reconstitution guidance comes only from research-chemical vendor literature.
Recommended Injection Sites
- ✓Abdominal subcutaneous tissue (community-reported)
- ✓Anterior thigh subcutaneous tissue (community-reported)
🧊Storage Requirements
Lyophilised powder: refrigerate (2-8 C) for long-term storage. Reconstituted solution: refrigerate and use within 14-28 days per general short-peptide guidance. No Prostamax-specific stability data are available in PubMed-indexed literature.
Research Tools
Before You Begin
Review safety warnings and contraindications before starting any protocol.
Prostamax (KEDP) Dosing: Reported Protocols and Major Caveats#
There is no FDA-, EMA-, MHRA-, or Health Canada-approved dose for Prostamax. This page summarises dosing patterns reported in Khavinson-group literature and self-experimenter communities; none has been validated in a registered clinical trial. Treat all numbers below as investigational reference points rather than recommendations. Last verified June 4, 2026.
Reported Protocols#
Russian Clinic / Khavinson Framework (Oral)#
The Khavinson bioregulation framework historically used short oral courses of bioregulator peptides in the low-microgram-per-kilogram range, taken sublingually, in 10-20 day blocks followed by extended off-periods (often several months) before the next course. The specific Prostamax dose used in clinic practice is described in Russian-language sources from the St. Petersburg Institute and is not PubMed-indexed.
Community-Reported Subcutaneous Protocol#
Vendor packaging and self-experimenter community discussion typically describes:
- Dose: 1-2 mg per subcutaneous injection
- Frequency: daily or every other day
- Duration: 10-20 day courses
- Cycle: repeat once or twice yearly
These figures are not derived from human pharmacokinetic studies and are not directly comparable to oral microgram-scale historical use. There is no validated conversion between oral bioregulation-clinic dosing and subcutaneous community dosing.
Reconstitution and Handling#
Prostamax is typically supplied as a lyophilised powder. General short-peptide handling applies:
- Reconstitute with bacteriostatic 0.9% sodium chloride
- Aim for a working concentration that allows convenient measurement (e.g., 1 mg per 0.1 mL)
- Inject subcutaneously with a 28-31 gauge insulin syringe (community practice)
- Rotate injection sites between abdominal and anterior thigh subcutaneous tissue
Caveat: None of the above is product-specific. Prostamax has no FDA-recognised manufacturer, no cGMP product label, and no clinical stability data. The handling guidance is borrowed from general short-peptide practice and may not reflect optimal conditions for KEDP specifically.
Storage#
- Lyophilised powder: refrigerate (2-8 C) for long-term storage; protect from light
- Reconstituted solution: refrigerate and use within 14-28 days per general short-peptide guidance
- No Prostamax-specific stability data are available in PubMed-indexed literature
Why Self-Experimentation Is Not Recommended#
- Mechanism not validated. Independent biophysical confirmation of KEDP-DNA binding is absent (see Prostamax research).
- PK data absent. Plasma concentrations, half-life, and tissue distribution after either oral or subcutaneous Prostamax in humans are not reported.
- No dose-response data. The relationship between dose and any meaningful clinical outcome is unknown.
- Adulteration risk. Research-chemical-grade material is subject to identity and purity concerns; independent third-party testing is rare and not standardised.
- Effective alternatives exist. For symptomatic BPH, alpha blockers (tamsulosin, alfuzosin) and 5-alpha reductase inhibitors (finasteride, dutasteride) have decades of randomised trial evidence and are accessible by prescription.
Related Reading#
- Prostamax research and evidence base
- Prostamax side-effects profile
- Prostamax risks and legal status
- Epitalon dosing (comparable Khavinson short-peptide handling)
- Vesugen dosing
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles · 30+ comparisons · 18 research tools
Protocol updates
Get notified when we update dosing protocols or publish related comparisons.
Frequently Asked Questions About Prostamax
Is there an FDA-approved Prostamax dose?
No. Prostamax is not FDA-, EMA-, MHRA-, or Health Canada-approved. There is no regulator-sanctioned dose. Any dose found online or in vendor literature reflects either Russian bioregulation-clinic practice or self-experimenter convention, neither of which has been validated by randomised trial.
How is Prostamax typically administered?
Reported routes include oral (sublingual or oral capsule) and subcutaneous injection after reconstitution with bacteriostatic water. The Khavinson framework historically emphasised low-dose, short-course protocols repeated periodically rather than continuous administration. No route has been validated for human bioavailability in a PubMed-indexed pharmacokinetic study.
What is the typical reported Prostamax cycle length?
Self-reported community protocols generally describe 10-20 day courses followed by extended off-periods (months). This pattern mirrors the general Khavinson bioregulation philosophy of short, repeatable courses rather than continuous use. None of these schedules has been validated by clinical trial evidence.
What are the safety considerations for Prostamax dosing?
Because no controlled trial data exists, dose-response and adverse-event relationships are unknown. The most prudent stance is that any Prostamax use is investigational, that material purity is not guaranteed, and that symptomatic BPH or other prostate concerns warrant evaluation by a clinician rather than self-administration.
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.